Grants and Contributions:
Title:
Preclinical development of bifunctional therapeutic agents for cancer immunotherapy
Agreement Number:
908737
Agreement Value:
$137,838.00
Agreement Date:
Jun 1, 2018 - May 31, 2019
Description:
The goal of the project is to develop broadly effective immune therapeutic agents for the treatment of cancer.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V6P 6T3
Reference Number:
172-2018-2019-Q1-908737
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
783571292
Recipient Type:
For-profit organization
Recipient's Legal Name:
CureImmune Therapeutics Inc.
Federal Riding Name:
Vancouver Granville
Federal Riding Number:
59036
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410